Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 8/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA9 | Q16790 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7270552 | 0.83 | KLK7 (0.44) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL29398857 | 0.83 | KLK7 (0.53) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL29401167 | 0.82 | KLK7 (0.61) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL3912355 | 0.82 | KLK7 (0.61) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL10532627 | 0.80 | KMT2A (0.43) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL5169290 | 0.80 | ALDH1A1 (0.43) | KLK7ALDH1A1KMT2ACA2CA1 | |
| SCHEMBL5709593 | 0.80 | ALDH1A1 (0.43) | KLK7ALDH1A1KMT2ACA2CA1 | |
| Trifluoroacetic Acid SCHEMBL3910234 | 0.77 | KLK7 (0.41) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL7257138 | 0.75 | MAPT (0.45) | KLK7TLR2TLR1ALDH1A1KMT2A | |
| SCHEMBL6163528 | 0.75 | KLK7 (0.56) | KLK7TLR2TLR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-5246959-A | POLY(AMINOALKYL)AMINOCARBONYL AMINOACYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5229420-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5229369-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0355331-A2 | Poly(aminoalkyl)aminocarbonyl aminoacyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-02-28 | — | — | EP | disclosed |
| US-4902706-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents | G. D. SEARLE & CO. (US) | 1990-02-20 | — | — | US | disclosed |
| US-4900745-A | Poly(aminoalkyl)aminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4900746-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000052-A1 | POLY(AMINOALKYL)AMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0349921-A2 | Etheral n-terminal aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | KLK7 3083/4885TLR2 4806/4885TLR1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.